Tiziana Life Sciences announces six-month clinical results of foralumab

Tiziana Life Sciences announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale, MFIS, scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis, na-SPMS, patients participating in an Expanded Access, EA, Program. This follows on from previously announced positive six-month PET scan data which was presented at ECTRIMS 2023. “I am pleased to see the continued clinical response to intranasal foralumab from patients enrolled in our expanded access na-SPMS program,” stated Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System. “Notably, in this latest clinical update for patients EA 3 through EA 6, we have seen improvement in the Modified Fatigue Impact Scale scores in three out of four patients, which is significant since fatigue is a major complaint in this population. We have also seen various degrees of improvement in the Expanded Disability Status Scale, Timed 25-Foot Walk Test, pyramidal function scores and NeuroQoL Fatigue scores in a disease state that typically shows a decline in function over time.”